PA
PANC.US Panacos Pharmaceuticals Inc
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -667.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2008.
Is PANC.US undervalued?
Graham numberThe Graham number of Panacos Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Panacos Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Panacos Pharmaceuticals Inc yet.
Panacos Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Panacos Pharmaceuticals Inc
Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founde…
Full company profilePanacos Pharmaceuticals Inc financial statements
2008 annualized: Fiscal year 2008 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2008, the balance sheet is the latest quarter. Figures change when the annual report is published.
Panacos Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 40.7M | 26.9M | 4.23M | 716K | 1.34M | 1.05M | 284K | 180K | 103K |
| Gross Profit | - | - | - | - | 1.34M | 1.05M | 284K | 180K | 103K |
| Operating Income | - | - | - | - | -9.57M | -24.4M | -36.3M | -37.8M | -33.3M |
| Net Income | - | - | - | - | -12.0M | -59.1M | -38.1M | -37.5M | -35.2M |
| Balance Sheet | |||||||||
| Total Assets | 63.7M | 43.2M | 22.8M | 17.3M | 6.33M | 91.6M | 65.7M | 55.7M | 29.7M |
| Total Liabilities | 18.6M | 10.4M | 9.90M | 5.03M | 2.86M | 5.97M | 6.97M | 26.8M | 24.5M |
| Shareholders' Equity | 45.2M | 32.8M | 12.9M | 12.2M | 3.47M | 85.6M | 58.7M | 28.9M | 5.27M |
| Cash & Short-term Investments | 7.77M | 21.9M | 7.25M | 4.26M | 4.88M | 87.1M | 33.1M | 37.9M | 21.4M |
| Cash Flow | |||||||||
| Operating Cash Flow | - | - | - | - | -9.77M | -21.6M | -29.6M | -31.0M | -32.0M |
| Capital Expenditure | 6.09M | 1.73M | 1.48M | 91.0K | 76.0K | 150K | 519K | 48.0K | 108K |
| Ratios | |||||||||
| ROE | - | - | - | - | -346.6% | -69.0% | -64.9% | -129.8% | -667.8% |
| ROA | - | - | - | - | -190.1% | -64.5% | -58.0% | -67.2% | -118.4% |
| Net Profit Margin | - | - | - | - | -900.4% | -5,631.8% | -13,419.0% | -20,810.6% | -34,293.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Panacos Pharmaceuticals Inc dividends
Panacos Pharmaceuticals Inc has not paid dividends in the last 8 fiscal years.
Last stock split: 1:10 on Mar 15, 2005.
Who owns Panacos Pharmaceuticals Inc
Ownership data of Panacos Pharmaceuticals Inc is not available yet.
Panacos Pharmaceuticals Inc company profile
- Company name
- Panacos Pharmaceuticals Inc
- Ticker
- PANC.US
- Exchange
- USA Stocks
- Listed since
- Jun 10, 1998
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Fiscal year end
- December
- Address
- 134 Coolidge Avenue, Watertown, MA, United States, 02472
- Phone
- 617 926 1551
- Website
- -
About Panacos Pharmaceuticals Inc
Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.